Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12192287 | 0.82 | FFAR3 (0.36) | FFAR3 | |
| SCHEMBL12192293 | 0.76 | FFAR3 (0.31) | FFAR3 | |
| SCHEMBL12192277 | 0.71 | FFAR3 (0.33) | FFAR3 | |
| SCHEMBL10049998 | 0.71 | HSP90AA1 (0.42) | FFAR3 | |
| SCHEMBL441051 | 0.70 | HSP90AA1 (0.31) | — | |
| SCHEMBL12192234 | 0.69 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL12192224 | 0.69 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL439019 | 0.69 | HSP90AA1 (0.30) | — | |
| SCHEMBL12192337 | 0.67 | TAS2R38 (0.33) | — | |
| SCHEMBL12216288 | 0.66 | MEN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140342999-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8729111-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120065235-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065235-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | FFAR3 3618/4885 |
| US-20140342999-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | FFAR3 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.